📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Hilton Metal Forging Extends Rights Issue Closing Date to April 02, 2026
Hilton Metal Forging Limited has extended the closing date of its ongoing Rights Issue from March 13, 2026, to April 02, 2026. The company is offering 1,67,70,000 equity shares at a price of Rs. 1,668 per share to existing shareholders. The entitlement ratio is set at 29 shares for every 60 shares held. While the subscription period is extended, the trading of Rights Entitlements (REs) on the exchanges remains suspended as per the original schedule.
Key Highlights
Rights Issue closing date extended by 20 days to April 02, 2026
Issue involves 1,67,70,000 equity shares at a fixed price of Rs. 1,668 per share
Rights entitlement ratio is 29:60 (29 shares for every 60 shares held)
Trading in Rights Entitlements (REs) will not be extended and remains suspended
The issue originally opened on March 06, 2026
💼 Action for Investors
Eligible shareholders who intended to participate but missed the earlier deadline now have until April 02 to subscribe. Investors should compare the current market price with the issue price of Rs. 1,668 before making a decision.
HILINFRA Proposes Expansion into Hospitality, Toll Management, and Renewable Energy
Highway Infrastructure Limited is seeking shareholder approval via postal ballot to significantly broaden its business scope. The proposed changes to the Memorandum of Association include entering the hospitality, healthcare, and renewable energy sectors. Furthermore, the company plans to engage in toll collection and management services for various infrastructure projects. This move suggests a strategic pivot towards a diversified infrastructure and services model.
Key Highlights
Proposed addition of Clause III A (5) to MoA covering hotels, hospitals, malls, and sports complexes.
Proposed addition of Clause III A (6) for toll collection and management on highways and expressways.
Expansion into green energy including solar parks, wind farms, and EV charging infrastructure.
Remote e-voting period set for March 13, 2026, to April 11, 2026, with results by April 13, 2026.
💼 Action for Investors
Investors should monitor the company's upcoming capital expenditure plans and project announcements related to these new segments. While diversification can provide new revenue streams, the execution risk in non-core areas like hospitality and renewable energy should be carefully assessed.
Shilchar Technologies Shareholders Approve Director Appointments and Remuneration Hike
Shilchar Technologies Limited has announced the successful passage of four key resolutions via postal ballot with over 99.99% shareholder approval. The resolutions include the appointment of Mr. Aatman Alay Shah as a Director and Whole-Time Director, along with the appointment of an Independent Director. Additionally, shareholders approved a remuneration increase for Mr. Aashay Alay Shah, another Whole-Time Director. The voting process concluded on March 6, 2026, with near-unanimous support from participating shareholders.
Key Highlights
Appointment of Mr. Aatman Alay Shah as Whole-Time Director approved with 99.998% votes in favor.
Remuneration increase for Whole-Time Director Mr. Aashay Alay Shah passed with 99.997% majority.
Appointment of an Independent Director secured 99.998% approval from participating shareholders.
A total of 120-121 members participated in the remote e-voting process representing over 7.25 million votes for key resolutions.
💼 Action for Investors
These are routine governance approvals indicating strong shareholder support for the current management and leadership structure. Investors should continue to monitor the company's operational performance under this confirmed leadership team.
Shilpa Medicare Receives NCLT Approval for Merger with Shilpa Therapeutics
The National Company Law Tribunal (NCLT), Bengaluru Bench, has sanctioned the Scheme of Amalgamation between Shilpa Therapeutics Private Limited and its parent company, Shilpa Medicare Limited. As the transferor is a wholly-owned subsidiary, no new shares will be issued, and the existing share capital of the subsidiary will stand cancelled. The merger, with an appointed date of April 1, 2023, aims to streamline corporate structure and integrate operations. The company is now in the process of filing the certified order with the Registrar of Companies to make the merger effective.
Key Highlights
NCLT Bengaluru Bench approved the merger of Shilpa Therapeutics (subsidiary) into Shilpa Medicare (parent) on February 27, 2026.
No new shares will be issued as the transferor is a 100% subsidiary of the transferee company.
The appointed date for the amalgamation is fixed as April 1, 2023.
Statutory dues of ₹61.17 lakhs for the subsidiary and ₹3.59 crores for the parent were noted as of FY24 for settlement.
The authorized share capital of both entities will be clubbed, and all employees will be absorbed into Shilpa Medicare.
💼 Action for Investors
Investors should view this as a positive step toward corporate simplification and operational synergy. Since no new shares are being issued, there is no equity dilution for existing shareholders.
Hilton Metal Forging to Increase Authorized Share Capital to Rs 85 Crore; EGM on March 26
Hilton Metal Forging Limited has called for an Extraordinary General Meeting (EGM) on March 26, 2026, to seek shareholder approval for a significant increase in its authorized share capital. The proposal aims to raise the capital limit from Rs 55 crore to Rs 85 crore, representing a 54.5% increase in the authorized ceiling. This move is a standard precursor to future equity-based fundraising activities, such as a rights issue, bonus issue, or preferential allotment. Shareholders registered as of the cut-off date of March 18, 2026, will be eligible to vote on this resolution.
Key Highlights
Proposed increase in authorized share capital from Rs 55 crore to Rs 85 crore
Total equity shares to increase from 5.5 crore to 8.5 crore with a face value of Rs 10 each
Extraordinary General Meeting (EGM) scheduled for March 26, 2026, via Video Conferencing
Cut-off date for voting eligibility is March 18, 2026, with remote e-voting starting March 23
Amendment of Clause V of the Memorandum of Association to reflect the new capital structure
💼 Action for Investors
Investors should watch for follow-up announcements regarding specific fundraising plans or expansion projects that this capital increase is intended to support. While the increase itself is a procedural step, it signals potential equity dilution or growth-oriented capital expenditure in the near future.
Hilton Metal Forging Approves ₹27.97 Cr Rights Issue at ₹16.68 Per Share; Ratio 29:60
Hilton Metal Forging Limited has approved the final terms for its rights issue to raise approximately ₹27.97 crores. The company will issue up to 1,67,70,000 equity shares at a price of ₹16.68 per share, including a premium of ₹6.68. Eligible shareholders as of the record date, February 24, 2026, can subscribe in a ratio of 29 shares for every 60 shares held. The subscription window is scheduled to open on March 6 and close on March 13, 2026.
Key Highlights
Total fundraise of up to ₹2,797.24 Lakhs through 1,67,70,000 equity shares.
Rights entitlement ratio fixed at 29 equity shares for every 60 shares held.
Issue price set at ₹16.68 per share, which is 1.67 times the face value.
Issue period scheduled from March 6, 2026, to March 13, 2026.
Last date for on-market renunciation of rights entitlements is March 10, 2026.
💼 Action for Investors
Eligible shareholders should compare the rights issue price of ₹16.68 with the current market price to decide between subscribing or renouncing their rights. Investors who do not wish to subscribe should sell their rights entitlements on the exchange before March 10 to avoid value dilution.
Hilton Metal Q3 PAT Surges 211% YoY to ₹1.41 Cr; 9M Profit Doubles to ₹3.31 Cr
Hilton Metal Forging reported a robust YoY performance for Q3 FY26, with revenue rising 73% to ₹69.84 crore. Net profit witnessed a sharp increase of 211% YoY, reaching ₹1.41 crore compared to ₹0.45 crore in the previous year. For the nine-month period ending December 2025, the company recorded a PAT of ₹3.31 crore, effectively doubling the ₹1.65 crore earned in the same period last year. Despite the strong YoY growth, there was a sequential decline in revenue and profit compared to Q2 FY26.
Key Highlights
Revenue from operations grew 73.3% YoY to ₹69.84 crore from ₹40.29 crore in Q3 FY25
Net Profit (PAT) surged 211% YoY to ₹1.41 crore against ₹0.45 crore in the year-ago period
Nine-month revenue reached ₹179.53 crore, already surpassing the full-year FY25 revenue of ₹163.05 crore
Earnings Per Share (EPS) for the quarter increased significantly to ₹0.61 from ₹0.19 YoY
Total expenses for the quarter stood at ₹68.80 crore, with raw material costs accounting for ₹65.12 crore
💼 Action for Investors
The company exhibits strong growth momentum with 9-month profits already exceeding the previous full year's performance. Long-term investors should focus on the significant YoY expansion, though the sequential dip suggests monitoring for operational volatility.
Highway Infrastructure Bags ₹15.64 Cr NHAI Order for Katiyara Fee Plaza Operations
Highway Infrastructure Limited (HILINFRA) has received a Letter of Acceptance from the National Highways Authority of India (NHAI) for a contract worth ₹15.64 crore. The order involves the operation and collection of user fees at the Katiyara Fee Plaza located on NH-319 in Bihar. This domestic contract has a short execution timeline of 90 days. The scope also includes the maintenance of adjacent toilet blocks and management of consumables at the site.
Key Highlights
Total contract value awarded by NHAI is ₹15,63,99,930
Project involves user fee collection at Katiyara Fee Plaza, Rohtas district, Bihar
The contract duration is specified as 90 days for execution
Includes upkeep and maintenance of adjacent toilet facilities at the plaza
💼 Action for Investors
This short-term contract provides immediate revenue visibility; however, investors should monitor the company's ability to secure longer-term O&M projects. Watch for execution efficiency as these fee-collection contracts typically operate on high-volume, tight-margin models.
Shilpa Medicare Subsidiary Partners with SteinCares to Launch Biosimilar in Latin America
Shilpa Medicare's subsidiary, Shilpa Biologicals, has entered into a strategic licensing agreement with SteinCares to commercialize a biosimilar across Latin America. SteinCares will hold exclusive rights to register and distribute the product across 30 countries in the region, while Shilpa will handle development and long-term manufacturing from its Dharwad facility. This agreement marks Shilpa Biologicals' first entry into the Latin American market, a significant step in its global biosimilar expansion. The partnership leverages SteinCares' 45 years of regional expertise to provide cost-effective specialty treatments.
Key Highlights
Exclusive licensing agreement with SteinCares for biosimilar distribution in 30 Latin American countries.
Shilpa Biologicals to provide long-term commercial manufacturing from its Dharwad, India facility.
Marks the first product from this strategic partnership and Shilpa's entry into the Latin American market.
SteinCares brings over 45 years of experience in specialty healthcare and biosimilars in the region.
Focuses on high-value therapeutic areas including immunology, oncology, and ophthalmics.
💼 Action for Investors
Investors should view this as a positive step towards diversifying revenue streams and entering high-growth international markets. Monitor for future regulatory approvals and product launch timelines in specific Latin American countries to gauge revenue impact.
Highway Infrastructure Bags ₹154.60 Cr NHAI Contract for Fee Plaza Operations in Gujarat
Highway Infrastructure Limited has officially signed a contract agreement with the National Highways Authority of India (NHAI) for user fee collection operations. The contract is valued at approximately ₹154.60 Crores and involves managing the Moti Naroli, Ena, and Gandevi Fee Plazas on the Vadodara-Mumbai Expressway in Gujarat. The project has a short execution timeline of 90 days, providing immediate revenue visibility for the company. This follows the Letter of Acceptance previously received on February 16, 2026.
Key Highlights
Awarded a contract worth ₹154,59,99,930 by the National Highways Authority of India (NHAI).
Scope includes user fee collection at Moti Naroli, Ena, and Gandevi Fee Plazas on the Vadodara-Mumbai Expressway.
The contract covers multiple sections of the expressway spanning from Ankleshwar to Gandeva in Gujarat.
Execution timeline is set for a period of 90 days.
Includes additional responsibility for the upkeep and maintenance of adjacent toilet blocks.
💼 Action for Investors
Investors should view this as a positive development for short-term revenue growth and monitor the company's ability to secure similar high-value operational contracts from NHAI.
Hilton Metal Forging Sets Feb 24 as Record Date for 29:60 Rights Issue
Hilton Metal Forging Limited has officially fixed February 24, 2026, as the record date for its upcoming Rights Issue. Eligible shareholders will be entitled to receive 29 new equity shares for every 60 fully paid-up equity shares held as of the record date. This corporate action is part of the company's capital raising strategy and will lead to an expansion of the equity base. Investors should note that the record date determines who receives the rights entitlements in their demat accounts.
Key Highlights
Record date for the Rights Issue is Tuesday, February 24, 2026
Rights entitlement ratio is 29 shares for every 60 shares held
The issue is conducted under Regulation 42 of SEBI (LODR) Regulations, 2015
The move will result in equity dilution for shareholders who do not subscribe to the rights
💼 Action for Investors
Existing shareholders should check the rights issue price once announced to determine if it is at a discount to the market price. If you wish to participate, ensure you hold the shares before the ex-date to be eligible for the 29:60 entitlement.
Hilton Metal Forging to Raise Rs 27.97 Cr via Rights Issue; Ratio 29:60
Hilton Metal Forging Limited has approved a Rights Issue of 1,67,70,000 equity shares at a price of Rs 16.68 per share. The total fundraise is valued at approximately Rs 27.97 crore to support the company's capital requirements. The board has fixed February 24, 2026, as the record date for determining eligibility. Existing shareholders will be entitled to 29 new shares for every 60 shares they hold, leading to significant equity dilution.
Key Highlights
Issue price of Rs 16.68 per share includes a premium of Rs 6.68 over face value
Rights entitlement ratio set at 29 shares for every 60 shares held as of Feb 24, 2026
Total equity shares to increase from 3.47 crore to 5.15 crore assuming full subscription
Authorized share capital increased from Rs 55 crore to Rs 85 crore to accommodate the issue
Full payment of Rs 16.68 per share is required at the time of application
💼 Action for Investors
Investors should compare the issue price of Rs 16.68 with the current market price to assess the attractiveness of the offer before the record date of February 24.
Hilton Metal Forging Approves Q3 FY26 Standalone Financial Results
Hilton Metal Forging Limited has officially approved its standalone financial results for the quarter ended December 31, 2025. The Board of Directors met on February 14, 2026, to review the performance and the Limited Review Report. The meeting was conducted efficiently, lasting approximately 45 minutes. Investors should now look for the detailed financial statements to evaluate the company's operational margins and revenue growth for the period.
Key Highlights
Board approved standalone financial results for the quarter ended December 31, 2025
The Board Meeting commenced at 5:00 P.M. and concluded at 5:45 P.M. on February 14, 2026
Limited Review Report for the third quarter was reviewed and taken on record
Compliance maintained under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
💼 Action for Investors
Investors should review the detailed profit and loss statements once fully published to assess the company's growth trajectory. Compare the Q3 performance against previous quarters to determine if the company is maintaining its margins in the forging sector.
Shilpa Medicare Secures Strategic CDMO Partnership with NXI Therapeutics AG
Shilpa Medicare has entered into a strategic partnership with Swiss biotech firm NXI Therapeutics AG for the development and commercial manufacturing of a New Chemical Entity (NCE) targeting autoimmune disorders. This marks the company's third major international mandate in recent months, reinforcing its growing presence in the global CDMO market. The agreement covers the entire product lifecycle, including CMC development, clinical supply, and long-term commercial manufacturing. While financial terms remain confidential, the deal includes milestone-linked expansion potential and strengthens Shilpa's high-value innovation pipeline.
Key Highlights
Strategic partnership with NXI Therapeutics AG for development and commercial manufacturing of a novel NCE.
Third significant international mandate secured by Shilpa Medicare in recent months.
Scope includes CMC development, process scale-up, GMP clinical supply, and long-term commercial manufacturing.
Focuses on the high-growth autoimmune and immune-modulation therapeutic segment.
Agreement includes milestone-linked expansion potential for future revenue visibility.
💼 Action for Investors
Investors should view this as a positive development in Shilpa Medicare's transition toward becoming a high-value CDMO partner for global biotech firms. Monitor the execution of these international mandates as they are key drivers for long-term revenue growth and margin improvement.
Shilpa Medicare Signs Strategic NCE Development Agreement with Swiss-based NXI Therapeutics
Shilpa Medicare has entered into a binding agreement with Switzerland's NXI Therapeutics AG for the development and supply of a New Chemical Entity (NCE) targeting autoimmune disorders. This marks the company's third major international mandate in recent months, reinforcing its transition into a high-value CDMO partner. The collaboration covers the full product lifecycle, including CMC development, clinical studies, and long-term commercial GMP manufacturing. While specific financial terms are confidential, the deal includes milestone-linked expansion potential and enhances long-term revenue visibility.
Key Highlights
Third significant international development and manufacturing contract secured in recent months.
Partnership covers the entire lifecycle from early development to long-term commercial GMP manufacturing.
Targets the high-growth autoimmune and alloimmune therapeutic segment globally.
Agreement includes milestone-linked expansion potential and strengthens the company's CDMO platform.
Collaboration with Swiss-based NXI Therapeutics leverages Shilpa's integrated R&D and manufacturing infrastructure.
💼 Action for Investors
Investors should monitor the progress of this NCE through clinical stages as it validates Shilpa's CDMO capabilities and provides long-term growth visibility. The stock remains a positive watch for those looking at the evolving Indian biotech and specialty manufacturing space.
HILINFRA Q3 FY26: Record Order Book of ₹1,160 Cr and 34% YoY PAT Growth
Highway Infrastructure Limited reported a 34.3% YoY increase in consolidated PAT to ₹6.3 crores for Q3 FY26, while 9M FY26 PAT surged 121.5% to ₹23.1 crores. The company's consolidated order book reached a record ₹1,160 crores as of January 2026, a 4x increase compared to March 2025. Management highlighted the acquisition of the ₹328.8 crore Kaza Fee Plaza mandate as a transformative milestone for their tolling vertical. The company is diversifying geographically into Gujarat and the Northeast while maintaining a 77% government client mix.
Key Highlights
Consolidated order book reached ₹1,160 crores, a 181% increase since September 2025
9M FY26 Standalone PAT grew by 192% YoY to ₹22.9 crores
Secured the company's largest tollway collection mandate worth ₹328.8 crores in Andhra Pradesh
EPC vertical has visibility for ₹400-450 crores in project completions over the next two years
77% of the customer mix consists of government entities, ensuring payment security
💼 Action for Investors
The massive jump in the order book provides strong revenue visibility for the next two fiscal years; investors should monitor execution efficiency. The transition to an asset-light tolling model is a positive structural shift that could significantly improve long-term return ratios.
HILINFRA Bags ₹64.69 Crore NHAI Contract for Mundka Fee Plaza Operations
Highway Infrastructure Limited (HILINFRA) has signed a formal contract agreement with the National Highways Authority of India (NHAI) for toll collection operations. The contract involves the operation and collection of user fees at the Mundka Fee Plaza in Delhi and Haryana for a period of 90 days. Valued at approximately ₹64.69 Crores, the project also includes the maintenance of adjacent facilities. The company is scheduled to take over the plaza operations on February 26, 2026.
Key Highlights
Contract awarded by National Highways Authority of India (NHAI) for the Mundka Fee Plaza.
Total contract consideration is valued at ₹64,68,99,930.
The execution period for the contract is set for 90 days.
Official takeover of the fee plaza is scheduled for February 26, 2026.
Scope includes user fee collection and upkeep of adjacent toilet blocks and consumables.
💼 Action for Investors
Investors should view this as a positive short-term revenue driver, though the 90-day duration suggests it is a temporary mandate. Monitor if the company can convert such short-term NHAI contracts into long-term operational assets.
Shilpa Medicare Q3 FY26: Highest Ever Revenue of ₹411 Cr and 41% EBITDA Growth
Shilpa Medicare reported its highest-ever quarterly performance with revenue reaching ₹411 crores, a 28% YoY increase, and EBITDA growing 41% to ₹115 crores. The company's adjusted PAT for the first nine months of FY26 at ₹146 crores has already nearly doubled the full-year PAT of FY25. Growth is primarily driven by a 50% surge in the formulations business and strong traction in the European market. Management is shifting focus from heavy R&D investment to execution, with significant product launches like Rotigotine and NorUDCA expected to drive future ROCE.
Key Highlights
Reported highest-ever quarterly revenue of ₹411 crores, up 28% YoY, and EBITDA of ₹115 crores, up 41% YoY.
Formulation business revenue grew 50% YoY to ₹177 crores, with European formulation sales increasing over 100%.
Adjusted ROCE (excluding long-term R&D) improved significantly to over 17% in 9M FY26 from 3.5% in FY23.
Received EMA approval for Rotigotine transdermal patch with launch planned for Q1 FY27 and ADC facility commissioning in Q4 FY26.
9M FY26 PAT of ₹146 crores nearly doubles the total PAT recorded in the entire previous fiscal year (FY25).
💼 Action for Investors
Investors should view the strong operating leverage and improving ROCE as a sign of successful transition from an investment phase to a commercialization phase. Monitor the upcoming launch of Rotigotine in Europe and the progress of the high-value Biologics and ADC pipeline for long-term value.
Rushil Decor Reports Zero Deviation in Utilization of Rs 93.04 Cr Preferential Issue Funds
Rushil Decor Limited has successfully utilized the entire realized amount of Rs 93.04 crores from its preferential issue of convertible warrants. The company confirmed zero deviation from the intended objects, which primarily focused on expanding laminate manufacturing and MDF plant upgrades. While the total issue size was Rs 122.66 crores, the company forfeited Rs 9.87 crores due to non-conversion, resulting in a final realized amount of Rs 93.04 crores. This is the final disclosure on this matter as all funds are deployed and no warrants remain pending.
Key Highlights
Total realized proceeds of Rs 93.04 crores fully utilized as of December 31, 2025.
Rs 80.00 crores deployed for the Jumbo size decorative laminates manufacturing project at Mansa.
Rs 9.87 crores forfeited till December 31, 2025, under SEBI (ICDR) Regulations.
Audit Committee and CARE Ratings Limited confirmed zero deviation or variation in fund usage.
Final disclosure issued as the purpose of the fundraise is completed with no pending warrants.
💼 Action for Investors
Investors should take confidence in the company's disciplined capital allocation and the completion of funding for the Mansa laminate project. The lack of deviation suggests transparent management execution regarding growth-oriented capital expenditure.
Highway Infrastructure Q3 PAT Rises 38% YoY; Order Book Hits Record ₹1,160 Cr
Highway Infrastructure Limited (HILINFRA) reported a strong Q3 FY26 with standalone PAT growing 38% YoY to ₹6.1 crore and 9M FY26 PAT surging 191.7% to ₹22.9 crore. The company's order book reached a historic high of ₹1,160 crore as of January 2026, representing a 50% growth since September 2025. A major driver is the recent win of its largest-ever tollway collection contract worth ₹328.8 crore in Andhra Pradesh. Management is targeting the completion of ₹400-450 crore worth of EPC projects over the next two years to sustain this momentum.
Key Highlights
Consolidated order book grew 50% in four months to reach ₹1,160 crore as of January 2026
Standalone 9M FY26 PAT witnessed a massive 191.7% YoY jump to ₹22.9 crore
Secured the largest-ever single tollway contract worth ₹328.8 crore for Kaza Fee Plaza in Andhra Pradesh
EPC order book increased by 49.5% from March 2025 levels to reach ₹623.6 crore
Standalone EBITDA margins improved significantly to 7.4% in Q3 FY26 from 5.4% in Q3 FY25
💼 Action for Investors
The significant jump in the order book provides strong revenue visibility for the next 24 months. Investors should monitor the execution pace of the ₹400+ crore EPC pipeline and the margin sustainability as the company scales its tollway operations.